Summary. Jugular administration of 200 \g=m\g PGI-2 salt significantly reduced spontaneous uterine activity in ovariectomized, oestrogen-primed goats; the effect was acute and persisted for about 3 h. Peripheral plasma concentrations of 6-keto-PGF-1\g=a\, the stable metabolite of PGI-2, decreased to 50% of initial values after 30 min; but at the start of uterine recovery were in excess of 2 ng.ml \m=-\1. Uterine reactivity to both oxytocin and PGF-2\g=a\after PGI-2 administration was unaffected.
Introduction
Prostaglandins (PG) of the E and F series are generally considered to be the key prostanoids involved in the modulation of uterine activity. However, a role for prostacyclin (PGI-2), a potent vasodilator and inhibitor of platelet aggregation (Moneada et al, 1976) , has to be defined. PGI-2 is present in the myometrium and endometrium of non-pregnant and pregnant animals including rats, guinea-pigs, sheep (Jones et al, 1977; Williams et al, 1978) , goats (Cooke & Homeida, 1987) and women (Omini et al, 1979) . In-vitro experiments have produced conflicting results: PGI-2 may either inhibit (Omini et al, 1979) or stimulate and then inhibit the pregnant human myometrium (Wikland et al, 1983) ; myometrial activity in the rat, however, is stimulated (Williams et al, 1979) . Lye & Challis (1982) showed that PGI-2 inhibited both the electrical and mechanical activity of the non-pregnant sheep uterus in vivo, but responsiveness to PGF-2a and oxytocin were unaffected.
The aims of this study were to examine in ovariectomized goats the effect of PGI-2 on spontaneous uterine activity, and also the effects of PGI-2 on uterine reactivity to both PGF-2a and oxytocin.
Materials and Methods
Animals and treatments. Four mature female goats of mixed breeding but similar age (3^t years) and weight (40) (41) (42) (43) (44) (45) kg) were used. The animals, anaesthetized with sodium thiopentone intravenously and maintained with fluothane and oxygen, were ovariectomized through a left-flank incision. A soft polyethylene, air-filled balloon (27 5 mm; Portex Ltd, Hyde, Kent, UK) attached to a more rigid 40-cm length of cannula was inserted into the uterus via a small incision in the uterine wall; intrauterine pressure was monitored by a Bell and Howell pressure transducer and recorded on a Devices MX-2 machine. Details of the techniques have been described previously (Jones & Knifton, 1975) . Following a post-surgical recovery period of 10 days all 4 animals were treated daily with 60 pg oestradiol benzoate (Intervet, Cambridge, UK) intramuscularly (i.m.) for 7 days.
On the 6th day of oestradiol administration 200 pg PGI-2 sodium salt (Upjohn Co., Kalamazoo, MI, USA) in 1 ml sterile saline (0-9% w/v NaCl) were injected into the jugular vein of each goat using 23-gauge needles. Uterine activity was recorded for 30 min before and for 2-5 h after PGI-2 administration. Jugular venous blood was collected by direct venepuncture into chilled heparinized tubes immediately before treatment and then at 10-min intervals for 120 min. Plasma was separated, snap-frozen in C02-acetone and stored at 6-oxo-PGF-lo, the stable metabolite of PGI-2. Before administration of PGI-2, 1 ml saline had been injected to assess whether the drug vehicle produced any change in uterine motility. After a period of recovery (4 h) when uterine activity returned to that observed in the pre-injection phase, doseresponse relationships were determined to doses of oxytocin (Universal Biologicals, Cambridge, UK) and PGF-2u (Lutalyse: Upjohn Co.); both were suitably diluted in saline so that each was contained in a maximum of 1 ml, and were injected into the jugular vein. To minimize possible time-related effects doses of oxytocin and PGF-2ct were administered in random order; each was separated by a 15-min interval. The same sequence of injections was then repeated 20 min after administration of 200 pg PGI-2 as described above. Assay of6-keto-PGI-la. A specific radioimmunoassay for 6-keto-PGF-la was used as described by Liggins et al (1980) , utilizing their antiserum (4V-208) at a dilution of 1:10000; 6-keto [5, 8, 9 ,1 l,12,14,15(n)-3H]PGF-la (5000 c.p.m./tube) was obtained from Amersham International (Bucks, UK). Standard curves were constructed using pure 6-keto-PGF-la (Upjohn). The recovery of added tracer was 77 ± 15% (mean ± s.e.m., = 9) and results were corrected for extraction losses; the recovery of standards (20, 50, 500, 1000 pg) added to goat plasma was 19-1 ± 1-9, 52-6 ± 7-8, 489 ± 15-7 and 893 ± 22-8 pg (mean ± s.e.m., = 6). The non-specific binding was 8%, the sensitivity of the assay lOpg/tube, and the intra-and inter-coefficients of variation were 6-2 and 12-6%, respectively (n = 12). Antiserum specificity has been reported previously (Liggins et al, 1980 
Results
Injection of 1 ml saline vehicle did not have any effect on uterine motility in the 4 goats. Figure 1 shows a representative trace of the effects of PGI-2 (200 µg) on uterine motility in one ovariecto¬ mized goat during treatment with oestradiol benzoate. There was a rapid decline in activity within 10 min, with a peak effect after about 30 min. Activity returned slowly and was still significantly (P < 001) below pre-injection values after 2-0 h. The results for all 4 animals are presented in Fig.  2 . Concentrations of 6-keto-PGF-la decreased progressively to 50% of initial values after about 30 min; at the start of the recovery period concentrations were still greater than 2 ng.mP '. Table 1 shows the mean responses to various doses of intravenous oxytoxin and PGF-2a before and after treatment with 200 µg PGI-2. Reactivity to both agents, at all dose levels, was not significantly ( < 005) affected, i.e the dose-response curves for both oxytocin and PGF-2a were unaltered by PGI-2, even though spontaneous activity was significantly (P < 0-001) reduced.
Discussion
The results of this study show that PGI-2 inhibits spontaneous uterine motility in the goat; similar results have been reported for the sheep (Lye & Challis, 1982) . Such an acute effect of PGI-2 may be of importance in rendering the uterus quiescent before implantation when progesterone concen¬ trations are very low (Thorburn & Schneider, 1972; Irving et al., 1972) . This is supported by several observations. While PGI-2 is present in the goat corpus luteum, highest concentrations of its metabolites, 6-keto-PGF-2a, have been found in the myometrium and endometrium, and concen¬ trations increase significantly during early pregnancy (Cooke & Homeida, 1987) ; in this respect it may be beneficial to compare uterine activity, and responses to PGI-2, in non-pregnant and early pregnant goats. PGI-2 has also been shown to regulate uterine blood flow in the rat (Kennedy & Zamecnik, 1978) , to assist blastocyst implantation in women (Kelly, 1981) , and be luteotrophic in the cow both in vitro and in vivo (Milvae & Hansel, 1980) . The prolonged effect of PGI-2 on the goat uterus was surprising considering its short half-life of 3 min in blood or biological buffers (Dusting et al, 1978) . It is possible that 6-keto PGF-2a is responsible for the inhibitory effect, but the uterus recovered when plasma concentrations of the metabolite were in excess of 2 ng.ml~', and also it has been reported that 6-keto-PGF-2a has no effect on human myometrial activity in vitro (Omini et al, 1979) . However, bearing in mind the possible species differences in uterine responses to PGI-2 referred to above, it would be useful to examine the effects of the metabolite on uterine motility in ruminants.
As observed in ovariectomized ewes (Lye & Challis, 1982) 
